In mid-May, the Indian government announced plans to double the number of drug inspectors and install quality testing facilities at ports within the next three years as part of a $500 mil. plan to increase India’s drug regulatory capacity. The increase in its oversight program follows in the wake of recent compliance actions taken by the US and Europe against some of India’s key manufacturers, including import bans, warning letters, and a consent decree against Ranbaxy (see IPQ April 28, 2014).
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
